MiniVax, Inc. and University of Rochester Enter into Option for Antibody Treatment against Pneumocystis pneumonia

NEW ORLEANS & ROCHESTER, N.Y.–(BUSINESS WIRE)–MiniVax, Inc. (New Orleans, LA) and the University of Rochester (Rochester, NY) announce that they have entered into an exclusive option agreement with agreed licensing terms to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia (PCP). The antibody of interest is a product of research conducted at the University of Rochester. PCP is a life-threatening, fungal respiratory infection that affects patients with weakened immune systems such as those suffering from HIV/AIDS, receiving organ transplants, and undergoing chemotherapy.

<--read more–>